Advanced Therapies Week 2022 | Differences in supply chains in the CGT industry

Julia Tarasenko, MSc, Marken, Durham, NC, comments on the complexity of the supply chain in the cell and gene therapy (CGT) sector. Due to the nature of the products themselves, the manufacturing, storage and administration of these therapies require a supply chain more complicated than that of standard pharmaceutical products. She additionally emphasizes the need to create a robust supply chain, and adapt to the needs of patients who may have disease with limited treatment options. This interview took place at Advanced Therapies Week 2022.